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Background. Whether long-term benzodiazepine users who participate in a family practice-
based benzodiazepine discontinuation programme substitute benzodiazepines by other psycho-
tropics is not clear.
Objective. To evaluate the impact of a benzodiazepine discontinuation programme on non-
benzodiazepine psychotropic prescription in family practice.
Methods. In family practices in the Netherlands, 2425 long-term benzodiazepine users partici-
pated in a two-step benzodiazepine discontinuation programme. The programme started with
a discontinuation letter (Step 1). Subjects unable to stop (N = 1707) were offered participation
in Step 2, a three-group randomized trial with a taper procedure with group psychotherapy, a
taper without psychotherapy and usual care. Only 156 subjects agreed to participate. The com-
parison group consisted of 1821 long-term users from family practices not participating in the
programme. The main outcome was the change in prescription of non-benzodiazepine psycho-
tropic medication from baseline (3 months before the start of the programme) till 21 months after
the start of the programme. Four logistic regression models were performed concerning antide-
pressant prescription in the follow-up.
Results. Only antidepressants were prescribed in relevant numbers. The prescription of antide-
pressants was not related to the programme. (P-value of experimental versus control group varied
between 0.18 and 0.85 in the four models). The most important predictor of antidepressant pre-
scription in follow-up was baseline antidepressant prescription [odds ratio (OR): 67.2; 95% confi-
dence interval (95% CI): 49.8–90.7]. Subjects, of whom the prescription of benzodiazepines had
been discontinued completely, had been prescribed less antidepressants (OR: 0.8; 95% CI: 0.6–1.0).
Conclusion.An effective benzodiazepine reduction programme was not accompanied by a sub-
stitute use of other psychotropics.
Keywords. Family medicine, mental health, prescribing, substance misuse.
Introduction
Benzodiazepines are effective drugs in the short-term
treatment of insomnia and anxiety.1 The clinical efficacy
of long-term benzodiazepine use, however, has not been
established satisfactorily.2 Above that, long-term benzo-
diazepine use is associated with benzodiazepine depen-
dence, increase of fall-risk and impairment of cognitive
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function.1,2 Therefore, interventions to decrease long-
term use in the large population of users in family prac-
tice are sensible. Several benzodiazepine discontinuation
programmes have shown to be successful in decreasing
the number of long-term benzodiazepine users.3–9 Up till
now, however, it is not clear whether benzodiazepine
discontinuation programmes lead to changes in the pre-
scription of other psychotropic medications. Data of psy-
chotropic use after benzodiazepine discontinuation are
scarce. Evaluations of the New York State triplicate pre-
scription regulation suggested a possible increase of pre-
scription of other, more harmful, psychotropics when
benzodiazepine prescription decreased.10 Initiation of
other psychotropics after benzodiazepine discontinua-
tion may be expected for several reasons such as psychi-
atric co-morbidity, patient pressure and treatment of
benzodiazepine withdrawal symptoms.
As these agents may carry comparable side effects
as benzodiazepines, like increased fall-risk,11 it is im-
portant to know whether discontinuation of benzodia-
zepines leads to changes in prescription of these other
psychotropics. This may provide a more adequate
risk-benefit estimation of benzodiazepine discontinua-
tion programmes.
Recently, the current authors carried out a stepwise
programme to reduce long-term benzodiazepine use in
a large family practice-based population (the Benzore-
dux programme). An intention to treat analysis was
performed comparing the effectiveness of the benzodi-
azepine discontinuation programme in long-term benzo-
diazepine users in family practices, to which the
programme was offered, with usual care control practi-
ces. Both intervention steps, a discontinuation letter
(Step 1) and a subsequent, family practitioner guided,
taper scheme (Step 2), were effective in discontinuation
of benzodiazepine use, although additional group psy-
chotherapy (in Step 2) did not improve this outcome.5,8
Factors associated with benzodiazepine abstinence in
the programme were as follows: amount and duration
of initial benzodiazepine use, gender (Step 1) and ben-
zodiazepine dependence severity, as measured by the
Benzodiazepine Dependence Self-Report Question-
naire, amount of initial benzodiazepine use and alcohol
use (Step 2).8,12 Relapse in benzodiazepine use (mean-
ing restart of family practitioner prescription) was re-
lated to initial use of multiple benzodiazepines, use of
antidepressants and initial benzodiazepine type.12
In the present study, we evaluated the consequences
of the benzodiazepine discontinuation programme on
the prescription of non-benzodiazepine psychotropics
to the participants of the Benzoredux programme.
Materials and methods
Design
The Benzoredux programme was a prospective, con-
trolled, stepped-care and intervention programme in
family practice, aimed to reduce long-term benzodiaz-
epine use.5,8 The study was carried out between
August 1998 and December 2001. The intervention
consisted of a discontinuation letter, followed by an
evaluation consultation after 3 months. At this consul-
tation, persistant users were asked to participate in
step two: a three-group Randomized Controlled Trial
with a taper scheme by the family practitioner, with
(group A) or without group psychotherapy (group B)
and a usual care control condition (group C). (The
usual care controls did not receive any help with ben-
zodiazepine reduction and were informed about the
randomization result by letter).
Study population
Subjects were regarded as long-term benzodiazepine
users when they fulfilled two conditions: (i) they had
received prescriptions for benzodiazepines for more
than 3 months and (ii) they had used an amount of
benzodiazepines sufficient for 60 days of use according
to the family practitioner prescription rules within the
last 3 months before inclusion in the programme.
Baseline values were obtained of 2425 subjects from
27 family practices.5 Seven hundred and eighteen sub-
jects, of these 2425, were excluded for the intervention
due to exclusion criteria formulated by the research-
ers’ (N = 467) and family practitioners considerations
[N = 251 (=10%; the range per practice was 2–28% of
all includable subjects)] (Fig. 1). The discontinuation
letter was sent to the remaining 1707 subjects, of
which subsequently 156 (9%) were motivated for the
second intervention step after they had failed to dis-
continue due to the discontinuation letter alone.8
From a National Information Network of family
practices (LINH), at the end of the 21 months follow-
up, baseline and follow-up data were obtained from
1821 long-term benzodiazepine users from 16 regular
care control practices (Fig. 1). The LINH network is
a valid sample of all Dutch family practices.13 We in-
cluded all practices that used the same electronic med-
ical dossier (EMD) as in the experimental group and
with a complete registration period covering the study
period up to and including 1 year before the start of
the study. The practices corresponded on average with
the experimental practices regarding location and or-
ganizational type.5
Measurements
All practices had an EMD at the minimum for basic
patient administration and drug prescription. In total,
four different EMD systems were used by the partici-
pating practices. All prescription data of study partici-
pants were automatically extracted from the EMD
in the practice anonymously. An intervention starting
date was assigned to each subject being the date of
mailing the discontinuation letter. The subjects in the
experimental practices that were excluded for the
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discontinuation letter and all subjects from the control
group received an equivalent time point as interven-
tion starting date. The study period was divided into
3-month periods where each period in fact consisted
of 91 days exactly. By this, the baseline period was de-
fined as the 3-month time period prior to the interven-
tion starting date and the 21 months follow-up after
the baseline period was divided into seven periods of
3 months.
The following data and definitions were used.
1. Basic characteristics: gender, age and health insur-
ance status [private or National Health Service].
2. Baseline benzodiazepine use: the amount of benzo-
diazepine use in the baseline period was expressed
as the average prescribed daily dose (PDD), using
benzodiazepine equivalence rules by Zitman et al.9
(for instance, a PDD of 1 is equivalent with pre-
scription for average daily use of 10 mg diazepam).
3. Definition of a prescription: a prescription of a psy-
chotropic agent in a 3-month period was defined as
any prescript of the agent issued by the family practi-
tioner within the concerning 3-month time period.
With the psychotropic prescriptions two variables
were constructed: (i) the total number of prescrip-
tions in the concerning 3-month period and (ii) a di-
chotomous variable indicating either none (0) or at
least one prescription (1) of the specific agent in the
concerning 3-month period (prescription prevalence).
4. Definition of short-term benzodiazepine discon-
tinuation: the discontinuation letter suggested dis-
continuation of benzodiazepine use by gradually
bringing down the use. We therefore recorded dis-
continuation after a period of 3 months and not
immediately after the sending of the letter. Short-
term discontinuation was thus defined as the
absence of any benzodiazepine prescription in the
second 3-month period (i.e. four up to and includ-
ing 6 months) after mailing the letter. Persistant
users were defined as subjects receiving at least one
benzodiazepine prescription in the second 3-month
period after the mailing of the letter.
Analysis
We first performed a descriptive analysis of the course
of non-benzodiazepine psychotropic medications in
the experimental group and the control group. The
FIGURE 1 Study profile. *Lost to follow-up abbreviations: D = death, M = moved from the FP practice, U = reason unknown.
**FP = family practitioner
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following subgroups of psychotropic agents (anatomi-
cal therapeutical codes) were defined: antidepressants
(N06A), antipsychotics (N05A), non-benzodiazepine
hypnotics [i.e. zolpidem (N05CG01) and zopiclone
(N05CF01)], barbiturates (N05CA), anti-epileptics
(N03), hydroxyzine (N05BB01), meprobamate
(N05BC01) and buspirone (N05BE01).14 It appeared
that only antidepressants were prescribed in relevant
quantities (see Results). Therefore, the differences in
mean number of prescriptions of antidepressants per
period were statistically tested between the experi-
mental group and the control group. The analysis was
restricted to 21-month study completers (experimental
group: N = 2248 and control group: N = 1585). Statis-
tical comparisons within and between groups were
performed with chi-square tests and t-tests, at a two-
sided significance level of 0.05.
Logistic regression was performed to study the influ-
ence of several variables on the prescription of antide-
pressants in the follow-up. We used the following
independent variables: study group (experimental/con-
trol), short-term discontinuation of benzodiazepine
prescription (yes/no), prescription of an antidepressant
in the baseline period (yes/no), baseline benzodiaze-
pine prescription (PDD, continuous), gender, age
(three categories: <50, 50 to <75, >75 years) and
health insurance status. These variables were entered
in four explanatory multivariate models with the fol-
lowing dependent variables: (i) Model A: prescription
of an antidepressant in every 3-month period in the
follow-up (yes/no); (ii) Model B: no prescription of an
antidepressant in any 3-month period in the follow-up
(yes/no); (iii) Model C: at least one prescription of an
antidepressant in at least one 3-month period in the
follow-up (yes/no) and (iv) Model D: at least one pre-
scription of an antidepressant in each of two consecu-
tive 3-month periods in the follow-up (yes/no). (This
last model was chosen as a minimal treatment period
of a depression is considered to be 6 months)
Results
Table 1 shows baseline characteristics of the two study
groups. No statistically significant differences were
observed between the experimental and the control
group, except for baseline prescription of anti-epilep-
tics, which was higher in the experimental group
(P = 0.002).
No statistical differences were observed in the base-
line level of antidepressant prescription or in the fol-
low-up period between the experimental and control
group (Table 2).
With the dichotomous variable ‘prescription preva-
lence’ per period, we studied patterns of use during
the follow-up. Those who used antidepressants in the
baseline period had a high chance of using them in all
subsequent seven follow-up periods [experimental
group: N = 240 (53%) of a total of 452; control group:
N = 167 (52%) of a total of 319]. Furthermore, those
who did not have a prescription of an antidepressant
at baseline had a high chance of remaining abstinent
of antidepressant prescription during all seven follow-
up periods [experimental group: N = 1535 (85%) of
a total of 1796; control group: N = 1063 (84%) of a to-
tal of 1266].
The number of subjects that had a change in antide-
pressant prescription status, compared with baseline
period status, in at least one follow-up period was
comparable for the experimental and control groups
[N = 473 (21%) in the experimental group and
N = 355 (22%) in the control group], (P = 0.32). The
patterns of prevalences of prescription in the periods
in these subjects appeared to be very diverse and not
systematic.
Table 3 shows the results of the logistic regression
analysis in four explanatory models for antidepressant
prescription in the follow-up. Study group was no pre-
dictor of antidepressant prescription in any model. In
all models, baseline antidepressant prescription status
was the strongest predictor. Furthermore, in all mod-
els, discontinuation of benzodiazepine prescription at
short term was statistically related to receiving less an-
tidepressant prescriptions. Also, age was significantly
related in all four models, showing that a higher age
was related with less antidepressant prescription.
In both the experimental and the control groups,
the number of prescriptions of non-benzodiazepine
TABLE 1 Baseline characteristics of study subjects
Control
(N = 1585)
Experimental
(N = 2248)
Number of practices 16 27
Age (years) [mean (SD)] 63.9 (15.2) 61.8 (14.7)
Gender (% female) 73.1 71.0
Health insurance (% NHS) 80.5 80.0
Baseline benzodiazepine
prescription [average daily
PDD (SD)]
0.8 (0.8) 0.9 (1.0)
Baseline prescriptiona
Overall (all medications) 8.2 (6.8) 9.0 (9.8)
Overall, except benzodiazepines 5.39 (5.93) 5.95 (8.38)
Benzodiazepines 2.81 (2.03) 3.07 (2.45)
Anti-depressants 0.48 (1.21) 0.52 (1.26)
Non-benzodiazepine hypnoticsb 0.04 (0.38) 0.04 (0.34)
Anti-psychotics 0.17 (0.85) 0.13 (0.75)
Anti-epileptics 0.05 (0.35) 0.12 (0.89)
Hydroxyzine 0.002 0.004
Buspirone 0.002 0.002
Meprobamate 0 0.001
Barbiturates 0.001 0.003
NHS = National Health Service.
aAverage number of prescriptions (SD) per subject in 3-month base-
line period.
bZolpidem (N05CG01) + zopiclone (N05CF01).
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hypnotics [zolpidem (N05CG01) and zopiclon
(N05CF01)] was low.
No significant changes in prescription were observed
in the follow-up (Table 2).
Prescriptions of meprobamaat (N05BC01), buspir-
one (N05BE01), hydroxyzine (N05BB01) and barbitu-
rates (N05CA) were not separately analysed due to
very low prevalences. No new users of these substan-
ces were observed.
The prevalence of use of anti-psychotics (N05A)
and anti-epileptics (N03) was low (Table 1). No signif-
icant changes were observed in the number of pre-
scriptions of these classes during the follow-up for the
experimental and control groups.
Discussion
The main finding of this study was that an effective
benzodiazepine reduction programme in primary care
did not increase the prescription of other psychotropic
medication. Participation in this programme did not
alter the group prevalence of antidepressant use.
Apart from the follow-up of the New York State
triplicate prescription programme (TPP), in the 90s,
data on consequences of benzodiazepine discontinua-
tion programmes are scarce. In the TPP programme,
complication of benzodiazepine prescription by gov-
ernmental rules might have increased prescriptions of
other psychotropics, like meprobamaat, hydroxyzine
TABLE 2 Mean number of prescriptions (SD) per subject per 3 months of antidepressants (ATC: N06A) and non-benzodiazepine hypnotics [zol-
pidem (ATC: N05CG01) + zopiclone (ATC: N05CF01)] in the experimental group (N = 2248) and control group (N = 1585)
Category Baseline 3-month periods in follow-up
–3 to 0
months
0–3
months
4–6
months
7–9
months
10–12
months
13–15
months
16–18
months
19–21
months
Antidepressants Experimental 0.52 (1.26) 0.54 (1.35) 0.53 (1.33) 0.51 (1.28) 0.52 (1.28) 0.53 (1.29) 0.54 (1.33) 0.52 (1.28)
Control 0.48 (1.21) 0.49 (1.25) 0.45 (1.14) 0.45 (1.13) 0.46 (1.12) 0.48 (1.14) 0.51 (1.20) 0.48 (1.12)
Non-benzodiazepine
hypnotics
Experimental 0.04 (0.34) 0.04 (0.34) 0.04 (0.33) 0.04 (0.42) 0.03 (0.36) 0.03 (0.31) 0.03 (0.31) 0.03 (0.35)
Control 0.04 (0.38) 0.04 (0.37) 0.04 (0.39) 0.04 (0.35) 0.04 (0.35) 0.04 (0.35) 0.05 (0.42) 0.04 (0.37)
ATC, anatomical therapeutical code
TABLE 3 Adjusted ORs (95% CIs) of four multivariate logistic regression models in all subjects (N = 3833) explaining
antidepressant use in the follow-up
Dependent variable Model A Model B Model C Model D
Prescription of
an antidepressant
in every 3-month
follow-up period
(yes/no)
No prescription
of an antidepressant
in any 3-month
follow-up period
(yes/no)
At least one prescription
of an antidepressant
in the complete
21-month follow-up
(yes/no)
Prescription of an
antidepressant in the
21 months follow-up
in at least two
consecutive 3-month
periods (yes/no)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Study group (experimental = 1,
control = 0)
1.0 (0.8–1.4) 0.79 1.1 (0.9–1.4) 0.18 0.9 (0.7–1.1) 0.18 1.0 (0.8–1.2) 0.85
Benzodiazepine prescription
discontinuation (yes/no)
0.7 (0.5–1.0) 0.04 1.3 (1.0–1.7) 0.04 0.8 (0.6–1.0) 0.04 0.7 (0.5–0.9) 0.01
Baseline prescription of
AD (yes/no)
98.7 (67.0–145.2) <0.001 0.02 (0.01–0.02) <0.001 67.2 (49.8–90.7) <0.001 50.8 (39.9–64.6) <0.001
Baseline prescription of
benzodiazepine (PDD)
1.0 (0.9–1.1) 0.99 1.0 (0.9–1.1) 0.83 1.0 (0.9–1.1) 0.83 1.0 (0.9–1.1) 0.97
Gender (female = 1, male = 0) 1.0 (0.7–1.4) 0.98 1.1 (0.9–1.4) 0.26 0.9 (0.7–1.1) 0.26 0.8 (0.6–1.0) 0.11
Age (years)
<50 (reference) — — — —
50 to <75 0.9 (0.6–1.2) 0.34 1.7 (1.3–2.1) <0.001 0.6 (0.5–0.7) <0.001 0.6 (0.5–0.7) <0.001
>75 0.5 (0.3–0.8) 0.001 2.2 (1.7–3.0) <0.001 0.4 (0.3–0.6) <0.001 0.4 (0.3–0.5) <0.001
Health insurance
(private = 1, NHS = 0)
0.8 (0.6–1.2) 0.23 1.0 (0.8–1.3) 0.94 1.0 (0.8–1.3) 0.94 1.1 (0.9–1.5) 0.37
AD, antidepressant agent; NHS, National Health Service.
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and barbiturates.10 There was hardly any prescription
of these substances in our study groups which indi-
cates that prescription of these substances in this pri-
mary care group of long-term benzodiazepine users
has been virtually abandoned. Furthermore, the TPP
studies were performed in a different time span in
which for instance many of the modern antidepressant
agents were not available. Moreover, comparison with
the TPP programme fails as their intervention was
mainly directed towards the prescriber and the present
programme was mainly directed towards the user.
This study has several strengths that improve the
external validation and thus generalizability. A large
sample of subjects was included that was adequately
monitored by the family practitioner. Furthermore, an
intention to treat analysis was performed, in which those
subjects from the experimental practices that were ex-
cluded for the discontinuation programme were included
in the analysis. By doing so, selection bias was avoided in
the comparison with the control group. Another advan-
tage of this study is that we adjusted for possible seasonal
differences by choosing similar starting dates of the
intervention for the control and experimental groups.
Our a priori hypothesis was that quitting benzo-
diazepines could initiate new prescriptions of other
psychotropics. The baseline prescription of antidepres-
sants was high in this group of long-term benzodiaze-
pine users with an average of about 50 prescriptions
per 3 months in 100 subjects. Prediction analysis in
the Benzoredux study already showed that subjects
who use both an antidepressant and a benzodiazepine
do not have a higher chance of quitting benzodiaze-
pines, but when subjects succeed in quitting benzodia-
zepines, they are more capable of maintaining
benzodiazepine abstinence when being already on an
antidepressant.12 In the present study, no changes in
prescription of antidepressant agents were observed
between the experimental and the control groups.
However, the multivariate analysis showed that dis-
continuation of prescription of benzodiazepines was
associated with a lower chance to receive an antide-
pressant prescription in the follow-up compared with
persistant users. Whether this observation has clinical
significance is not clear. Psychiatric co-morbidity like
depression and generalized anxiety disorder may be
more present among the persistant users compared to
those who are able to discontinue benzodiazepine pre-
scription. Unfortunately, we were not able to study
this more in-depth as we did not have clinical diagno-
sis data. The present study in any case suggests that
quitting benzodiazepines as a result of this programme
in general does not initiate new antidepressant pre-
scriptions. This was supported by the observation of
a high level of consistency in antidepressant using sta-
tus from baseline till end of follow-up. The absence of
initiation of new psychotropics in long-term benzodi-
azepine users that were able to discontinue their
benzodiazepine prescription in this large study may
suggest that successfully discontinuating benzodiaze-
pines characterizes subjects that suffer less psychopa-
thology.
Finally, the baseline prevalence of prescription of
the more recently developed hypnotic agents zolpidem
and zopiclone was low, probably due to the fact that it
is not rational to have both a benzodiazepine and one
of the two other hypnotics prescribed (the agent zale-
plone is not available in the Netherlands). National
prescription data from Dutch pharmacies show an in-
crease of the prescription of zopiclone and zolpidem
in the period from 2001 till 2005 of 20% to 1.1 million
prescriptions in 2005. In this period, a decrease of pre-
scriptions of nitrazepam (18% to 0.5 million prescrip-
tions in 2005) was observed.15 This may suggest that
family practitioners in the Netherlands in general
more often prescribe zolpidem or zopiclone, in favour
of a long-acting benzodiazepine hypnotic. The impor-
tant finding in the present study was that no substitute
use with these hypnotics was observed in the follow-
up of this benzodiazepine discontinuation programme.
As both ‘epilepsy’ and ‘psychosis in medical history’
were exclusion criteria, the prevalence of use of anti-
psychotics (N05A) and anti-epileptics (N03) was low
among those receiving the actual intervention and no
significant changes were observed in the number of
prescriptions of these classes.
We conclude with the most important finding that
a benzodiazepine reduction programme in primary
care does not lead to substantial changes in prescrip-
tion of non-benzodiazepine psychotropic agents. Our
results thus indicate a pure advantage of preventing
complications when quitting benzodiazepines, as no
substitute use with associated risks was observed.
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